A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF IPTACOPAN (LNP023) IN COMPLEMENT 3 GLOMERULOPATHY

Registry ID

CLNP023B12301

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

NOVARTIS PHARMACEUTICALS CANADA INC

Start date

2022-02-07

Last update

2021-06-09

Conditions

• GLOMERULOPATHY

Related clinical trials

• AN OPEN-LABEL, NON-RANDOMIZED EXTENSION STUDY TO EVALUATE THE LONG-TERM EFFICACY, SAFETY AND TOLERABILITY OF IPTACOPAN (LNP023) IN C3 GLOMERULOPATHY OR IDIOPATHIC IMMUNE-COMPLEX-MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS

View on source registry